Trident Lifeline Ltd. · BSE:TLL
Trident Lifeline — Q2 FY27 Earnings Presentation
26 slides from Trident Lifeline's earnings presentation, Nov 5, 2026
Slide 1: BSE filing cover letter for Q2 FY27 earnings presentation
Date: 05.11.2026 BSE Limited Stock ID: TLL 14th Floor, P. J. Towers, Scrip Code: 543616 Dalal Street, Fort, ISIN: INE0MKA01014 Mumbai – 400001. SUB: EARNINGS PRESENTATION‐Q2 FY27. Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclo
Slide 2: Investor Presentation Trident Lifeline Limited Q2 FY27 Earnings Update
Investor Presentation Trident Lifeline Limited (TLL) Q2 FY27 EARNINGS UPDATE
Slide 3: Inside this presentation
Inside this presentation 03 08 11 19 20 Earnings About Our right Investment Financial update us to win rationale overview
Slide 4: Executive summary – Q2 FY27 (standalone financials)
03 | E A R N IN G S U P DA TES Executive summary – Q2 FY27 (based on standalone financials) Revenue and profitability Return and capital Client and people Revenue from operations Return on equity (ROE) Manpower 19% 210 bps 21% ₹32.7 crores 24.1% YoY growth 103 YoY growth YoY growth Operating profit
Slide 5: Executive summary – Q2 FY27 (consolidated financials)
04 | E A R N IN G S U P DA TES Executive summary – Q2 FY27 (based on consolidated financials) Revenue and profitability Return and capital Client and people Revenue from operations Return on equity (ROE) R&D and F&D investment 2 50% 267 bps 89% ₹47.1 crores YoY growth 24.9% YoY growth ₹0.7 crores Yo
Slide 6: Performance update and management commentary
05 | E A R N IN G S U P DA TES Performance update and management commentary Management commentary Our vision has always extended beyond strengthening our core pharmaceutical formulations business. We believe that developing complementary businesses will create additional avenues for growth and enabl
Slide 7: Performance update and management commentary
06 | E A R N IN G S U P DA TES Performance update and management commentary Management commentary Q2 FY27 has been encouraging for Trident Lifeline Limited, reflecting strong business growth, improved profitability, and continued progress towards our long-term strategic objectives. Our performance i
Slide 8: Revenue split across segments – Q2 FY27
07 | E A R N IN G S U P DA TES Revenue split across segments – Q2 FY27 (based on consolidated financials) Tablets Capsules Medical Devices Others1 11% -19% 183% 147% 7.4 6.8 17.0 17.2 5.5 15.5 3.0 6.0 Q2 FY26 Q2 FY27 Q2 FY26 Q2 FY27 Q2 FY26 Q2 FY27 H1 FY26 H1 FY27 Total 50% Revenue contribution (%)
Slide 9: Building a global healthcare platform
08 | A B O UT U S : C O MP A N Y O V E R VIE W Building a global healthcare platform The integrated trident ecosystem Trident at a glance Building a diversified manufacturing platform across formulations and medical devices ▪ Established in 2014 as an export-focused pharmaceutical company, building
Slide 10: An integrated model creating value across the pharmaceutical value chain
09 | A B O UT U S : O U R B U S IN E SS MO D E L An integrated model creating value across the pharmaceutical value chain Our operational excellence and OPERATIONAL VALUE CHAIN Procurement Manufacturing Exports strategic enablers create a self-reinforcing cycle of growth Consolidated manufacturing ▪
Slide 11: Building a global pharmaceutical platform
010 | A B O UT U S : O U R J O U R N EY Building a global pharmaceutical platform 2015 - 2016 2021 - 2022 2024 2025 2026 Company formation Market expansion Strategic growth Operational scale Building future pipeline ▪ Beginning of ▪ Plant approvals ▪ Commercial operation ▪ Commercial operation of ▪
Slide 12: Diverse product categories delivering broad therapeutic coverage globally
11 | O U R R IG H T T O W IN : E XT E N S IV E P R O DUCT P O R T FOL IO Diverse product categories delivering broad therapeutic coverage globally Product categories Therapeutic excellence *A/ = Anti A/ Bacterial A/ Diabetic Dental Range A/ Lipidemic Drug Oral Solids Liquids Tablet, Capsule, Dry Syr
Slide 13: A strong registration base is a high-barrier asset
12 | O U R R IG H T T O W IN : O U R C O R E A S S E T - R E G IS T RA TION S A strong registration base is a high-barrier asset that creates a compounding engine for long-term value Registration platform Our compounding growth engine Value created 1.5 – 3 years Cash generation Registrations Access
Slide 14: Key driver in creating innovative, market-ready solutions
13 | O U R R IG H T T O W IN : IN -H O U SE R & D A N D F & D U N IT Key driver in creating innovative, market-ready solutions End-to-end development capabilities R&D and F&D Investment (₹ crore) Provide : 1 Key value proposition ▪ Formulation development 0.8 F&D and R&D team ▪ Process development 0
Slide 15: Building manufacturing capabilities behind validated global demand
14 | O U R R IG H T T O W IN : H O W O U R MO D E L W O R K S Building manufacturing capabilities behind validated global demand Traditional pharma model Factory built before Heavy upfront capital Customer sought Long investment-to- Risk of idle Delayed return demand exists commitment after setup re
Slide 16: Accreditation from regulatory authorities
15 | O U R R IG H T T O W IN : W H Y U S Accreditation from regulatory authorities
Slide 17: Experienced leadership driving growth, governance and long-term value creation
16 | O U R R IG H T T O W IN : B O A R D O F D IR E C TORS Experienced leadership driving growth, governance and long-term value creation Mr. Hardik Mr. Shravan Mr. Ashish Ms. Rupaben Ms. Maniya Jigishkumar Desai Harikrishna Patel Bafna Chetan Jariwala Hardik Desai Chairman Managing Director Executi
Slide 18: Diverse independent board strengthens governance and strategic oversight
17 | O U R R IG H T T O W IN : B O A R D O F D IR E C TORS Diverse independent board strengthens governance and strategic oversight Dr. Mishal Shailesh Ms. Falguni Bhavesh Ms. Smita Kiran Davda Mr. Sachin Bhandari Patel Jariwala Independent Director Independent Director Independent Director Independ
Slide 19: Built presence across multiple emerging markets
18 | O U R R IG H T T O W IN : O U R P R E S EN C E Built presence across multiple emerging markets, creating a foundation for scalable growth Share of global registrations by region Our geographic presence Europe 1% Establishing presence and building growth CIS 21% Africa opportunities I Presence D
Slide 20: Building a larger, more profitable global pharmaceutical platform
19 | IN V E S T MEN T R A T IO N A L E: O U R G R O W TH D R IV E R S Building a larger, more profitable global pharmaceutical platform Why we believe growth can sustain Value creation framework 2,582 Larger registration Portfolio expansion Manufacturing 1 Registrations Registrations pipeline platfo
Slide 21: Income Statement and Cash Flow Statement (standalone)
20 | F IN A N C IA L O V E R VIE W Income Statement (based on standalone financials) All currencies is in ₹ crores, unless otherwise mentioned Particulars Q2 FY27 Q2 FY26 YoY change Q1 FY27 QoQ change Q4 FY26 Q3 FY26 FY26 Revenue from operations 32.7 27.4 19% 26.8 22% 32.0 23.7 101.9 Cost of materia
Slide 22: Balance Sheet (standalone financials)
21 | F IN A N C IA L O V E R VIE W Balance Sheet (based on standalone financials) All currencies is in ₹ crores, unless otherwise mentioned Equity and Liabilities FY24 FY25 FY26 H1 FY27 Assets FY24 FY25 FY26 H1 FY27 Share capital 11.5 11.5 11.9 12.0 Non-current assets: Reserves & surplus 41.2 54.2 8
Slide 23: Income Statement and Cash Flow Statement (consolidated)
22 | F IN A N C IA L O V E R VIE W Income Statement (based on consolidated financials) All currencies is in ₹ crores, unless otherwise mentioned Particulars Q2 FY27 Q2 FY26 YoY change Q1 FY27 QoQ change Q4 FY26 Q3 FY26 FY26 Revenue from operations 47.1 31.3 50% 33.7 40% 50.0 25.7 129.0 Cost of mater
Slide 24: Balance Sheet (consolidated financials)
23 | F IN A N C IA L O V E R VIE W Balance Sheet (based on consolidated financials) All currencies is in ₹ crores, unless otherwise mentioned Equity and Liabilities FY24 FY25 FY26 H1 FY27 Assets FY24 FY25 FY26 H1 FY27 Share capital 11.5 11.5 11.9 12.0 Non-current assets: Reserves & surplus 40.4 53.0
Slide 25: Safe harbor statement
Safe harbor statement Global market size (USD Bn) This presentation and the accompanying slides (the “Presentation”), which have been prepared by Trident Lifeline Limited (the “Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation
Slide 26: Get in Touch with Us
Get in Touch with Us For further information, please contact: Nikita Sharma Company Secretary compliance@tridentlifeline.com Our Investor Relations Partner Meeting Request Link Preet Choradiya Mr. Rutul Shah +91 73832 01103 +91 82002 47366 preet@atlascapital.in rutul@atlascapital.in